By Fineline Cube 
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) announced plans to acquire a 64.81% stake in Vietnamese pharmaceutical company Imexpharm Corporation for a total consideration of RMB 1.587 billion (USD 220 million). This strategic acquisition aims to expand Joincare’s market presence and leverage synergies in the Southeast Asian pharmaceutical market.
Business Synergy
Imexpharm Corporation is a Vietnamese pharmaceutical company that specializes in antibiotics, cardiovascular and cerebrovascular drugs. This business scope is highly complementary to Joincare Pharmaceutical’s existing product lines. The acquisition is expected to enhance Joincare’s product portfolio and strengthen its market position in both China and Vietnam.
Strategic Implications
The acquisition of a significant stake in Imexpharm Corporation underscores Joincare Pharmaceutical’s commitment to international expansion. By integrating Imexpharm’s capabilities and market reach, Joincare aims to accelerate growth and improve operational efficiency in the region.-Fineline Info & Tech